Zafgen, Inc. (NASDAQ:ZFGN) – Research analysts at Leerink Swann boosted their Q3 2017 EPS estimates for shares of Zafgen in a research note issued on Tuesday. Leerink Swann analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings per share of ($0.54) for the quarter, up from their prior estimate of ($0.58). Leerink Swann also issued estimates for Zafgen’s Q4 2017 earnings at ($0.59) EPS, FY2017 earnings at ($2.10) EPS, FY2018 earnings at ($1.39) EPS and FY2019 earnings at ($1.15) EPS.
Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. During the same quarter last year, the company posted ($0.55) earnings per share. COPYRIGHT VIOLATION NOTICE: This story was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/2802064/zafgen-inc-to-post-q3-2017-earnings-of-0-54-per-share-leerink-swann-forecasts-nasdaqzfgn.html.
A number of other equities research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Zafgen from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. ValuEngine raised shares of Zafgen from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th. Finally, Roth Capital began coverage on shares of Zafgen in a report on Thursday, April 20th. They set a “buy” rating and a $9.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. Zafgen has a consensus rating of “Hold” and an average price target of $24.33.
Zafgen (NASDAQ:ZFGN) opened at 3.33 on Friday. The firm’s market cap is $91.15 million. The company’s 50 day moving average is $3.51 and its 200-day moving average is $4.09. Zafgen has a 52 week low of $2.89 and a 52 week high of $5.46.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Spark Investment Management LLC raised its position in shares of Zafgen by 49.5% in the second quarter. Spark Investment Management LLC now owns 282,200 shares of the biopharmaceutical company’s stock valued at $990,000 after buying an additional 93,500 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Zafgen during the second quarter valued at $304,000. Paloma Partners Management Co raised its position in shares of Zafgen by 17.4% in the first quarter. Paloma Partners Management Co now owns 130,000 shares of the biopharmaceutical company’s stock valued at $606,000 after buying an additional 19,278 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Zafgen during the first quarter valued at $840,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Zafgen by 44.7% in the first quarter. Dimensional Fund Advisors LP now owns 443,311 shares of the biopharmaceutical company’s stock valued at $2,066,000 after buying an additional 136,849 shares in the last quarter. 52.54% of the stock is owned by institutional investors.
In related news, insider Dennis D. Kim acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was bought at an average cost of $3.39 per share, with a total value of $33,900.00. Following the acquisition, the insider now directly owns 21,443 shares in the company, valued at $72,691.77. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 21.20% of the stock is currently owned by company insiders.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.